ASP
ATRA icon

Adams Street Partners’s Atara Biotherapeutics ATRA Stock Holding History

Adams Street Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-185
Closed -$146K – 19
2015
Q3 		$146K Buy
+185
New +$226K 0.03% 14

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adams Street Partners's ATRA Position: Q4 2015 in Review

Adams Street Partners sold out of Atara Biotherapeutics (ATRA) in Q4 2015, closing a stake of 185 shares — an estimated $146K sold.

Adams Street Partners first reported a position in ATRA in Q3 2015 and held it in 1 quarter. The position peaked at $146K in Q3 2015. 85 funds tracked by Wall St. Rank hold ATRA as of Q4 2015.

  • Adams Street Partners reported no remaining Atara Biotherapeutics position as of Q4 2015 after selling out during the quarter.
  • Adams Street Partners sold 185 Atara Biotherapeutics shares in Q4 2015, an estimated $146K.
  • Adams Street Partners first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 1 quarter.
  • Adams Street Partners's Atara Biotherapeutics position peaked at $146K in Q3 2015.
  • 85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2015.

Based on Adams Street Partners's 13F filing for Q4 2015, filed 12 Feb 2016.